Evotec SE

  • WKN: 566480
  • ISIN: DE0005664809
  • Land: Germany

Nachricht vom 14.11.2019 | 11:27

EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES

DGAP-News: Evotec SE / Key word(s): Conference
14.11.2019 / 11:27
The issuer is solely responsible for the content of this announcement.

 

Hamburg, Germany, 14 November 2019:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following upcoming conferences in November and December 2019:

Jefferies London Healthcare Conference, London, UK

  • Date: Wednesday, 20 November 2019
  • Presentation: 20 November 2019, 8.00 am (GMT)
  • Venue: London, UK
  • Attendee: Enno Spillner, Chief Financial Officer
     

LBBW German Company Day, London, UK

  • Date: Thursday, 21 November 2019
  • Venue: London, UK
  • Attendee: Enno Spillner, Chief Financial Officer
     

German Equity Forum, Frankfurt, Germany

  • Date: Monday, 25 November 2019
  • Presentation: 25 November 2019, 11.30 am (CET)
  • Venue: Frankfurt am Main, Germany
  • Attendee: Dr Werner Lanthaler, Chief Executive Officer


Kempen's London Conference, London, UK

  • Date: Wednesday, 27 November 2019
  • Venue: London, UK
  • Attendee: Dr Werner Lanthaler, Chief Executive Officer
     

Berenberg European Corporate Conference, Surrey, UK

  • Date: Tuesday, 03 December 2019
  • Presentation: 03 December 2019, 11.00 am (GMT)
  • Venue: Surrey, UK
  • Attendee: Enno Spillner, Chief Financial Officer

 

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality
stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.
 

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec SE:
Gabriele Hansen, SVP Corporate Communications, Marketing & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

 



14.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.

News im Fokus

Daimler AG: Daimler erzielt Grundsatzeinigungen über die vergleichsweise Beilegung behördlicher und zivilrechtlicher Verfahren in den USA im Zusammenhang mit Diesel-Emissionen

13. August 2020, 18:22

Aktueller Webcast

windeln.de SE

H1/Q2 2020 Earnings Call

14. August 2020

Aktuelle Research-Studie

Media and Games Invest plc

Original-Research: Media and Games Invest plc (von First Berlin Equity Research GmbH): BUY

14. August 2020